Publications by authors named "Clemence Ginet"

Claim this Profile
A
Acadesine Circumvents Azacitidine Resistance in Myelodysplastic Syndrome and Acute Myeloid Leukemia.
Thomas Cluzeau, Nathan Furstoss, Coline Savy, Wejdane El Manaa, Marwa Zerhouni, Clemence Ginet

Int J Mol Sci· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BCL2L10 positive cells in bone marrow are an independent prognostic factor of azacitidine outcome in myelodysplastic syndrome and acute myeloid leukemia.
Valérie Vidal, Guillaume Robert, Laure Goursaud, Laetitia Durand, Clemence Ginet

Oncotarget· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DNA Damage and the Activation of the p53 Pathway Mediate Alterations in Metabolic and Secretory Functions of Adipocytes.
Bastien Vergoni, Pierre-Jean Cornejo, Jérôme Gilleron, Mansour Djedaini, Franck Ceppo, Clémence Ginet

Diabetes· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differentiation inducing factor 3 mediates its anti-leukemic effect through ROS-dependent DRP1-mediated mitochondrial fission and induction of caspase-independent cell death.
Alix Dubois, Clemence Ginet, Nathan Furstoss, Amine Belaid, Mohamed Amine Hamouda

Oncotarget· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of Noninfectious Uveitis Using Intravenous Administration of Collagen II-Specific Type 1 Regulatory T Cells.
Hélène Asnagli, Marie Jacquin, Nathalie Belmonte, Julie Gertner-Dardenne, Marie-Françoise Hubert, Clémence Ginet

Invest Ophthalmol Vis Sci· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Successful re-treatment of a relapsed V600E mutated HCL patient with low-dose vemurafenib.
Caroline Bailleux, Guillaume Robert, Clémence Ginet, Daniel Re, Antoine Thyss

Oncoscience· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low-dose vemurafenib induces complete remission in a case of hairy-cell leukemia with a V600E mutation.
Frederic Peyrade, Daniel Re, Clemence Ginet, Lauris Gastaud, Maryline Allegra

Haematologica· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to ponatinib.
Ophélie Cassuto, Maeva Dufies, Arnaud Jacquel, Guillaume Robert, Clémence Ginet

Oncotarget· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Simalikalactone E (SkE), a new weapon in the armamentarium of drugs targeting cancers that exhibit constitutive activation of the ERK pathway.
Guillaume Robert, Valérie Jullian, Arnaud Jacquel, Clémence Ginet, Maeva Dufies

Oncotarget· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis